S
Sari Laitinen
Researcher at University of Tampere
Publications - 5
Citations - 803
Sari Laitinen is an academic researcher from University of Tampere. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 5, co-authored 5 publications receiving 766 citations.
Papers
More filters
Journal ArticleDOI
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
Wennuan Liu,Sari Laitinen,Sofia Khan,Mauno Vihinen,Jeanne Kowalski,Guoqiang Yu,Li Chen,Charles M. Ewing,Mario A. Eisenberger,Michael A. Carducci,William G. Nelson,Srinivasan Yegnasubramanian,Jun Luo,Yue Wang,Jianfeng Xu,William B. Isaacs,Tapio Visakorpi,G. Steven Bova +17 more
TL;DR: It is shown through a high-resolution genome-wide single nucleotide polymorphism and copy number survey that most, if not all, metastatic prostate cancers have monoclonal origins and maintain a unique signature copy number pattern of the parent cancer cell while also accumulating a variable number of separate subclonally sustained changes.
Journal ArticleDOI
EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients.
Sari Laitinen,Paula M. Martikainen,Teemu Tolonen,Jorma Isola,Teuvo L.J. Tammela,Tapio Visakorpi +5 more
TL;DR: Ki‐67, EZH2 and MCM7 are potential prognostic biomarkers in prostatectomy treated patients and showed independent prognostic value with relative risks in multivariate analysis.
Journal ArticleDOI
Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization.
TL;DR: The identified genetic aberrations lay the groundwork for further detailed genetic analyses of these xenografts, suggesting that the transition of the growth from androgen dependency to independence does not involve major chromosomal aberration in these two models.
Journal ArticleDOI
Cellular changes in prostate cancer cells induced by intermittent androgen suppression.
TL;DR: The findings suggest that the long-term effect of androgen withdrawal on tumour growth is due to the inhibition of proliferation, suggesting that the biologic aggressiveness of a particular tumour is defined already at an early stage of disease.
Journal ArticleDOI